Twist Bioscience Launches Humanized Transgenic Mouse Model to Enhance Antibody Discovery Services

Twist Bioscience has launched a humanized transgenic mouse model to enhance antibody discovery services. The HuTg model offers a fee-for-service approach that accelerates lead discovery and optimization, allowing for the identification of fully human antibody hits in weeks. This innovation complements existing in vivo platforms and pairs well with Twist's DiversimAb mouse and B cell screening platforms.

Twist Bioscience Corporation (NASDAQ: TWST), a leading synthetic DNA technology company, has announced the launch of a humanized transgenic (HuTg) mouse model to enhance its antibody discovery services. The new offering aims to accelerate lead discovery and optimization, enabling the identification of fully human antibody hits in weeks rather than months. This innovation complements Twist's existing in vivo platforms and pairs well with its DiversimAb mouse and B cell screening platforms [1].

The HuTg mouse model generates robust immune responses and human antibody repertoires, streamlining the translation of research findings into clinical applications. Emily M. Leproust, CEO and co-founder of Twist Bioscience, noted that the model eliminates time-consuming licensing negotiations typically associated with such technologies, offering a fee-for-service approach that works within customers' budgets and timelines [1].

The launch of the HuTg mouse model comes as part of Twist's broader strategy to expand its antibody discovery capabilities and provide researchers with multiple methods that can be used independently or together across various disease areas. This move follows strong revenue growth of 25.3% over the last twelve months and a record revenue of $92.8 million for the second quarter of fiscal year 2025 [2].

Twist Bioscience's financial health remains robust, with a strong balance sheet and a healthy current ratio of 4.51, positioning it well for continued innovation. Analysts have generally maintained positive ratings on the company, with varying price targets reflecting both its growth potential and the need for strategic moves to reduce cash burn [2].

In conclusion, the launch of the HuTg mouse model by Twist Bioscience signifies a significant advancement in antibody discovery services, offering researchers greater flexibility and efficiency in their work. The company's commitment to innovation and strong financial position make it a notable player in the synthetic DNA technology sector.

References:
[1] https://www.marketscreener.com/news/twist-bioscience-expands-in-vivo-antibody-discovery-services-with-launch-of-humanized-transgenic-mou-ce7c5fdddb80ff21
[2] https://www.investing.com/news/company-news/twist-bioscience-launches-humanized-transgenic-mouse-model-93CH-4163019